Abstract 56P
Background
Inhibition of HIF-2α has had a substantial impact on the treatment paradigm for cancer patients with germline mutations in VHL. Preclinically, selective HIF-2α inhibitors demonstrate dramatic anti-tumor effects in xenograft models in which HIF-2α is a molecularly defined tumorigenic driver. However, therapeutic application of HIF-2α inhibitors beyond VHL-mutated clear cell renal cell carcinoma remains to be seen. In contrast to HIF-1α, HIF-2α has a more selective expression profile accompanying tailored regulons that may guide indications of interest.
Methods
The potential therapeutic benefit of HIF-2α inhibition in various oncology indications was investigated using bioinformatic, in vitro, and in vivo approaches. In mice, the role of HIF-2α in hepatocellular carcinoma (HCC) was investigated using an autochthonous high-fat diet carcinogen-induced tumor model.
Results
Consistent with the mechanism of action, inhibition of HIF-2α in various cell lines did not attenuate cell growth in 2D culture. However, significant alterations in the hypoxic gene signatures were detected, with substantial variation in HIF-2α-dependence. HIF-2α-specific gene signatures derived using pharmacological inhibition or genetic deletion applied to available datasets predicted poorer survival in multiple cancer indications, including renal (as validation) and liver. In an HCC mouse model, mice with deletion of HIF-2α in hepatocytes had significantly reduced number and size of liver nodules. These effects were apparent upon deletion of HIF-2α from birth or after tumors were established. Finally, mice treated with a HIF-2α inhibitor after tumor formation also had significantly decreased tumor burden.
Conclusions
HIF-2α plays a distinct and differential role in the transcriptional response to hypoxia in different tissue types and cell lines. In vivo data suggest that HIF-2α may contribute to the formation and progression of HCC, supporting clinical investigation of HIF-2α inhibition beyond ccRCC. AB521 is a potent and selective inhibitor that has been evaluated in healthy volunteers and is progressing through a phase Ib clinical trial in cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Arcus Biosciences, Inc.
Funding
Arcus Biosciences, Inc.
Disclosure
K.S. Gauthier, D. Piovesan, S. Cho,K.V. Lawson, K. Liao, P. Foster, T. Cheng, M. Walters: Financial Interests, Institutional, Stocks/Shares: Arcus Biosciences; Financial Interests, Institutional, Full or part-time Employment: Arcus Biosciences. Y. Shah: Financial Interests, Institutional, Funding: Arcus Biosciences. All other authors have declared no conflicts of interest.
Resources from the same session
38P - Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy
Presenter: Yujun Hu
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - Development of radiolabelled plerixafor as a theranostic molecule for targeting CXCR4 receptor expressing cancers: A translational study
Presenter: Tamanna Lakhanpal
Session: Cocktail & Poster Display session
Resources:
Abstract
41P - BRCA2 pathogenic variant (PV): A novel agnostic biomarker for immune checkpoint blockers (ICB)?
Presenter: Beatriz Alonso de Castro
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - Prognostic impact of the tumor immune microenvironment in adrenocortical cancer
Presenter: Nano Pachuashvili
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - HPV16-specific CD4 and CD8 T-cell activation and functionality in patients receiving combination PDS0101 immunotherapy
Presenter: Lauren Wood
Session: Cocktail & Poster Display session
Resources:
Abstract
45P - Discovery of CBO-212, a first-in-class drug Fc-conjugate (DFC), targeting CD73 in cancer
Presenter: James Levin
Session: Cocktail & Poster Display session
Resources:
Abstract
48P - Efficacy analysis and mechanism exploration of furmonertinib for advanced NSCLC with EGFR exon 20 insertion mutation
Presenter: Xiao Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - Treatment management in RAS and BRAF mutations in patients with metastatic colorectal cancer
Presenter: Merve Özkan
Session: Cocktail & Poster Display session
Resources:
Abstract
50P - KRAS mutation, the molecular landscape of lung adenocarcinoma in the Portuguese population
Presenter: Carolina Trabulo
Session: Cocktail & Poster Display session
Resources:
Abstract
51P - Toxicity profile in early clinical trials with fibroblast growth factor receptor (FGFR) inhibitors (FGFRi): 10-years experience of a drug development unit
Presenter: Katerin Rojas Laimito
Session: Cocktail & Poster Display session
Resources:
Abstract